Niacin suppresses microRNA‑93 in MASLD models — who this could help and when to wait for trials
New lab work from South Korea identifies microRNA‑93 (miR‑93) as a genetic driver of metabolic‑associated steatotic liver disease (MASLD) and…
Retatrutide Phase 3 (TRANSCEND‑T2D‑1) cut A1C up to 2.0% and body weight up to 16.8% after 40 weeks
Eli Lilly’s investigational triple agonist retatrutide produced large reductions in both A1C and body weight in TRANSCEND‑T2D‑1, a 537‑person Phase…
Semaglutide linked to significantly lower psychiatric risks in large Sweden and Australia studies
Two recent registry analyses from Sweden and Australia — together following nearly 100,000 adults, including more than 20,000 people who…
Lecanemab: Fc-Driven Microglial Plaque Clearance vs. Modest Clinical Gain and ARIA Risk
Lecanemab’s main action depends on its Fc fragment calling microglia into action: recent work from VIB and KU Leuven shows…
Weekly injectable extended‑release buprenorphine increased prenatal opioid abstinence and reduced serious maternal adverse events
An NIH‑supported randomized trial of 140 pregnant adults with opioid use disorder found that weekly injectable extended‑release buprenorphine produced higher…
Melatonin for Kids: Useful in Specific Cases, Risky as a Routine Fix
Melatonin can help some children—especially those with neurodevelopmental disorders or clear circadian shifts—but product variability, rising accidental exposures, and sparse…
Salanersen’s Phase 1b: a clear biomarker and motor signal in post–gene‑therapy SMA—Phase 3 will test whether it changes care
Biogen’s Phase 1b results for salanersen showed a pronounced drop in a neurodegeneration biomarker and measurable motor gains in children…
FLOW trial: Sulthiame produced dose-dependent 16–35% AHI reductions — a pharmacologic option for CPAP‑intolerant OSA patients
Sulthiame, an oral carbonic anhydrase inhibitor, cut apnea events in the FLOW Phase 2 trial by roughly 16–35% depending on…